The OCMX™ is pleased to announce the listing of Aplos Medical to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

EDEN PRAIRIE, MN, September 01, 2021 /24-7PressRelease/ — Aplos Medical is a pre-revenue medical device start-up company developing a game-changing acid reflux treatment device for the 100 million PPI failures, meaning patients whose Proton Pump Inhibitor (PPI) drugs stop working or are given them serious side effects. There are no good treatment options for them today. Aplos completed all preclinical requirements, received an FDA IDE approval to begin clinical studies, and just received its 3rd SBIR grant for starting the first human clinical study with up to 15 patients. The Company also established IP protection for its innovations.

The OCMX™ is pleased to announce the listing of Aplos Medical to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on Aplos Medical and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that Aplos Medical exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


We are developing Omega PF as an evolutionary revolution for the reflux treatments. Omega takes the best of the 80 years of treatment experience, improves upon it, and adds a much-needed dimension that never existed before. Omega-PF provides significant clinical values and a clear product differentiation. Significant clinical values with clear product differentiation.

Currently, effective reflux control means difficulty in swallowing for patients. Omega is the first to control reflux and allows easy swallowing.


• The first treatment since 1939 to add the new dimension of easy swallowing. Omega is the first treatment that controls reflux and allows easy swallowing.
• Simpler and easier to implement for a consistent better outcome for a better patient experience.
• Mitigated other side effects of current treatments such as erosion, is MRI compatible and durable.
• First ideal solution for the 100 million reflux patients failing their drug regimen and need a treatment, but do not accept current treatments because of their side effects.
• Technology is patented in the US, China and Europe


For Omega PF, the pathway is to complete a clinical feasibility trial followed by a pivotal clinical trial of 100 patients for a Pre-market Approval (PMA) for market launch. Having completed the preclinical requirements, received an FDA IDE approval, and just received the 3rd NIH SBIR grant, the company is starting the clinical feasibility trial process.

The product will the only product that can meet the needs of all reflux patients who need a treatment by solving the dysphagia and other problems common to current treatments. One percent of the patients who need a treatment represents a $5 billion market. We intend to build a successful company, but the attractiveness of Omega PF makes it an attractive acquisition target.


The experienced Management team has pioneered treatments in the medical industry.

Claude Tihon, PhD, Founder & CEO – Besides being a senior member in fortune 100 (Bristol Myers, Bayer and Pfizer) and smaller companies and putting many products to the marketplace, Dr. Tihon also initiated standard of practices in general surgery, urology, cancer drug screening and biotechnology.

John Mehawej – John is an outstanding engineer with experience from orthopedics, cardiovascular and project management. He is instrumental in providing all the engineering support functions that resulted in the successful design and manufacturing of the Ω-PF device.

Mark Rydell – Mark is an innovative R&D talent with experience in cardiovascular, urology and orthopedics and over 70 patents, and is an expert in converting ideas to working devices. Mark provided the first prototypes to allow the project to progress through the iterative development stages, and to the completion of the preclinical studies.


The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors.

The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

Aplos Medical gets listed on THE OCMX™

For the original version of this press release, please visit here